See more : JITF Infralogistics Limited (JITFINFRA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Compugen Ltd. (CGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Compugen Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Blue Foundry Bancorp (BLFY) Income Statement Analysis – Financial Results
- EverFocus Electronics Corporation (5484.TW) Income Statement Analysis – Financial Results
- FTAI Aviation Ltd. (FTAIM) Income Statement Analysis – Financial Results
- Kensoh Co.,Ltd. (7939.T) Income Statement Analysis – Financial Results
- Jack in the Box Inc. (JACK) Income Statement Analysis – Financial Results
Compugen Ltd. (CGEN)
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.46M | 7.50M | 6.00M | 2.00M | 0.00 | 17.80M | 0.00 | 712.00K | 9.28M | 12.37M | 3.55M | 242.00K | -424.00K | 1.12M | 250.00K | 338.00K | 180.00K | 215.00K | 646.00K | 4.03M | 8.83M | 11.10M | 11.36M | 6.89M | 3.24M |
| Cost of Revenue | 2.00M | 975.00K | 680.00K | 60.00K | 989.00K | 1.03M | 1.59M | 223.00K | 1.63M | 3.34M | 2.51M | 201.00K | 424.00K | 224.00K | 0.00 | 7.00K | 0.00 | 6.00K | 148.00K | 1.10M | 2.28M | 2.82M | 3.46M | 478.00K | -769.00K |
| Gross Profit | 31.46M | 6.53M | 5.32M | 1.94M | -989.00K | 16.77M | -1.59M | 489.00K | 7.64M | 9.02M | 1.04M | 41.00K | -848.00K | 891.00K | 250.00K | 331.00K | 180.00K | 209.00K | 498.00K | 2.93M | 6.55M | 8.28M | 7.91M | 6.41M | 4.01M |
| Gross Profit Ratio | 94.01% | 87.00% | 88.67% | 97.00% | 0.00% | 94.19% | 0.00% | 68.68% | 82.40% | 72.96% | 29.30% | 16.94% | 200.00% | 79.91% | 100.00% | 97.93% | 100.00% | 97.21% | 77.09% | 72.68% | 74.22% | 74.60% | 69.59% | 93.06% | 123.76% |
| Research & Development | 34.47M | 30.65M | 28.69M | 22.76M | 19.82M | 30.32M | 28.58M | 24.55M | 21.25M | 15.07M | 12.28M | 9.44M | 6.78M | 5.23M | 5.05M | 8.75M | 8.39M | 9.81M | 10.47M | 12.32M | 13.31M | 14.17M | 15.98M | 12.17M | 6.68M |
| General & Administrative | 9.73M | 10.32M | 10.86M | 9.81M | 8.41M | 8.04M | 7.63M | 7.35M | 6.01M | 5.45M | 4.85M | 3.46M | 4.59M | 2.91M | 2.15M | 3.50M | 0.00 | 0.00 | 0.00 | 3.61M | 4.38M | 5.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 244.00K | 932.00K | 842.00K | 871.00K | 651.00K | 1.63M | 1.19M | 1.17M | 1.31M | 838.00K | 962.00K | 684.00K | 610.00K | 633.00K | 681.00K | 996.00K | 0.00 | 0.00 | 0.00 | 5.54M | 6.57M | 3.78M | 0.00 | 0.00 | 0.00 |
| SG&A | 9.98M | 11.25M | 11.70M | 10.68M | 9.06M | 9.68M | 8.82M | 8.52M | 7.32M | 6.29M | 5.81M | 4.14M | 5.20M | 3.54M | 2.83M | 4.50M | 4.25M | 4.39M | 4.91M | 6.19M | 7.46M | 9.15M | 10.95M | 9.18M | 4.32M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -523.00K | -811.00K | -588.00K | 281.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.82M | 18.44M | 13.89M | 0.00 | 0.00 | 1.86M |
| Operating Expenses | 44.45M | 41.90M | 40.39M | 33.44M | 28.88M | 39.99M | 37.41M | 33.07M | 28.56M | 21.36M | 18.08M | 13.58M | 11.98M | 8.77M | 7.88M | 13.24M | 12.64M | 14.20M | 15.38M | 18.50M | 20.77M | 23.32M | 26.92M | 21.35M | 12.85M |
| Cost & Expenses | 46.45M | 42.87M | 41.07M | 33.50M | 28.88M | 41.03M | 37.41M | 33.30M | 30.20M | 24.70M | 20.59M | 13.78M | 11.98M | 8.99M | 7.88M | 13.25M | 12.64M | 14.21M | 15.52M | 19.60M | 23.04M | 26.14M | 30.38M | 21.83M | 12.09M |
| Interest Income | 3.24M | 1.74M | 894.00K | 1.77M | 935.00K | 643.00K | 523.00K | 728.00K | 815.00K | 346.00K | 169.00K | 301.00K | 0.00 | 0.00 | 0.00 | 502.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 31.00K | 27.00K | 25.00K | 42.00K | 32.00K | 620.00K | 508.00K | 705.00K | 755.00K | 330.00K | 141.00K | 240.00K | -306.00K | 241.00K | 65.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 476.00K | 482.00K | 461.00K | 715.00K | 989.00K | 1.39M | 1.59M | 1.48M | 1.11M | 658.00K | 370.00K | 299.00K | 179.00K | 201.00K | 264.00K | 477.00K | 633.00K | 996.00K | 2.39M | 1.76M | 2.68M | 2.90M | 4.28M | 4.99M | 1.86M |
| EBITDA | -12.52M | -35.37M | -34.61M | -31.50M | -27.04M | -21.83M | -35.46M | -31.10M | -19.81M | -12.34M | -17.04M | -13.27M | -11.81M | -7.68M | -7.37M | -12.03M | -11.83M | -13.08M | -12.49M | -13.81M | -12.20M | -12.15M | -14.74M | -9.94M | -6.99M |
| EBITDA Ratio | -37.41% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,891.51% | -767.09% | -4,566.00% | -3,835.80% | -6,578.33% | -6,095.81% | -1,967.49% | -353.89% | -138.26% | -109.45% | -126.73% | -145.13% | -215.32% |
| Operating Income | -12.99M | -35.37M | -35.07M | -31.50M | -28.88M | -23.23M | -37.41M | -32.58M | -20.92M | -12.34M | -17.04M | -13.54M | -11.98M | -7.88M | -7.63M | -12.91M | -12.46M | -13.99M | -14.88M | -15.58M | -14.22M | -15.04M | -19.02M | -16.18M | -8.85M |
| Operating Income Ratio | -38.83% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,825.24% | -706.55% | -3,051.60% | -3,820.12% | -6,922.22% | -6,508.37% | -2,303.10% | -386.81% | -161.07% | -135.57% | -167.42% | -234.74% | -273.34% |
| Total Other Income/Expenses | 3.21M | 1.74M | 871.00K | 1.80M | 820.00K | 628.00K | 339.00K | 1.10M | 1.15M | 1.76M | 3.46M | -86.00K | 0.00 | 675.00K | 3.79M | 401.00K | 1.00M | 1.94M | 900.00K | 1.86M | 2.77M | 2.84M | -348.00K | 1.30M | -18.00K |
| Income Before Tax | -9.78M | -33.64M | -34.20M | -29.70M | -28.06M | -22.60M | -37.07M | -31.49M | -19.77M | -10.73M | -13.58M | -13.63M | -12.00M | -7.44M | -3.84M | -12.51M | -11.46M | -13.88M | -14.66M | -15.14M | -13.55M | -13.40M | -19.37M | -14.87M | -8.87M |
| Income Before Tax Ratio | -29.24% | -448.48% | -570.05% | -1,484.90% | 0.00% | -126.96% | 0.00% | -4,422.19% | -213.14% | -86.80% | -382.73% | -5,631.40% | 2,831.13% | -667.62% | -1,537.20% | -3,701.48% | -6,365.56% | -6,457.67% | -2,269.35% | -375.94% | -153.57% | -120.79% | -170.48% | -215.85% | -273.90% |
| Income Tax Expense | 8.97M | 58.00K | -1.33M | -2.44M | -722.00K | -1.26M | -678.00K | 20.00K | 390.00K | 360.00K | 500.00K | -416.00K | 331.00K | -1.35M | -7.58M | -37.00K | 32.00K | -1.08M | -1.12M | -2.29M | -3.44M | -2.84M | -3.53M | -1.59M | -701.00K |
| Net Income | -18.75M | -33.69M | -32.87M | -27.26M | -27.34M | -22.60M | -37.07M | -31.51M | -20.16M | -11.09M | -14.08M | -13.63M | -12.00M | -7.20M | -3.83M | -12.53M | -12.11M | -13.02M | -13.98M | -13.72M | -11.44M | -12.20M | -15.14M | -13.40M | -8.13M |
| Net Income Ratio | -56.05% | -449.25% | -547.88% | -1,363.00% | 0.00% | -126.96% | 0.00% | -4,425.00% | -217.34% | -89.71% | -396.82% | -5,631.40% | 2,831.13% | -646.01% | -1,532.40% | -3,706.21% | -6,730.00% | -6,055.81% | -2,163.78% | -340.75% | -129.64% | -109.98% | -133.31% | -194.51% | -251.13% |
| EPS | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| EPS Diluted | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| Weighted Avg Shares Out | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 47.81M | 38.87M | 35.84M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
| Weighted Avg Shares Out (Dil) | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 48.39M | 38.87M | 36.25M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference
5 Best Penny Stocks Under $5 To Buy According To Analysts Right Now
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2021 Results - Earnings Call Transcript
7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings
Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
3 Penny Stocks Cathie Wood's ARK Invest Bought In 2021, Will You?
Why Compugen Stock Got Slammed Today
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2021 Results - Earnings Call Transcript
Compugen (CGEN) Stock Up on Bristol Myers' $20M Investment
Why Compugen Surged 14% Higher on Thursday
Source: https://incomestatements.info
Category: Stock Reports